Lexicon Pharma (LXRX) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.49 +0.68%
Revenue Growth %: -79.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
CCB, ESCA, MPT, More
Revenue Growth %: -79.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
CCB, ESCA, MPT, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $17.71 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda Pharmaceutical Company Limited (TAK) Reports Q3 EPS of JPY308.00; offers guidance
- Algoma Steel Group (ASTL) Misses Q3 EPS by 49c
- Towne Bank (TOWN) Tops Q3 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
